Mittal B B, Zimmer A M, Sathiaseelan V, Rosen S T, Radosevich J A, Rademaker A W, Saini A, Pierce M C, Webber D I, Spies S M
Department of Radiology, Northwestern University Medical School, Chicago, Illinois.
Cancer. 1992 Dec 15;70(12):2785-91. doi: 10.1002/1097-0142(19921215)70:12<2785::aid-cncr2820701210>3.0.co;2-i.
Many studies have demonstrated synergistic interaction between hyperthermia and radiation. This study was undertaken to determine whether hyperthermia could enhance the effect of radioimmunotherapy (RIT) in the treatment of human colon adenocarcinoma xenografts in nude mice.
The experiments were conducted in two parts. During the first part of the study, preliminary information was obtained regarding the effect of various temperatures (41 degrees C, 42 degrees C, and 43 degrees C for 45 minutes) and iodine-131-labeled anticarcinoembryonic antigen (CEA) monoclonal antibodies (RMoAb) with administered activity ranging from 130 +/- 19 microCi to 546 +/- 19 microCi on tumor regrowth delay (TRD) and volume doubling time. This information was used in Part 2 of the study, which included four groups of mice: (1) a control group, (2) a group treated with hyperthermia, (3) a group treated with RMoAb, and (4) a group treated with a combination of RMoAb and hyperthermia.
Maximum and significantly increased TRD was observed in the group treated with RMoAb and hyperthermia (slope, 0.057) compared with the control group (slope, 0.322), the hyperthermia-treated group (slope, 0.302), and the group treated with RMoAb alone (slope, 0.098). The ratio of the slopes between the groups treated with RMoAb and those treated with RMoAb and hyperthermia was 1.72. No correlation was detected between the percent of antibody uptake in the tumor and tumor regression in the groups treated with heat and RMoAb and those treated with RMoAb alone.
The results of these experiments show that hyperthermia increased the effectiveness of iodine-131-labeled anti-CEA monoclonal antibodies against human colon carcinoma xenografts in nude mice. This study offers a rationale for combining hyperthermia and low-dose radiation produced from RIT in clinical practice.
许多研究已证实热疗与放疗之间存在协同相互作用。本研究旨在确定热疗是否能增强放射免疫疗法(RIT)对裸鼠人结肠腺癌异种移植瘤的治疗效果。
实验分两部分进行。在研究的第一部分中,获取了关于不同温度(41℃、42℃和43℃,持续45分钟)以及碘-131标记的抗癌胚抗原(CEA)单克隆抗体(RMoAb)(给药活性范围为130±19微居里至546±19微居里)对肿瘤生长延迟(TRD)和体积倍增时间影响的初步信息。该信息用于研究的第二部分,其中包括四组小鼠:(1)对照组,(2)热疗组,(3)RMoAb治疗组,(4)RMoAb与热疗联合治疗组。
与对照组(斜率为0.322)、热疗治疗组(斜率为0.302)和单独RMoAb治疗组(斜率为0.098)相比,RMoAb与热疗联合治疗组观察到最大且显著增加的TRD(斜率为0.057)。RMoAb治疗组与RMoAb和热疗联合治疗组之间的斜率比为1.72。在热疗和RMoAb联合治疗组以及单独RMoAb治疗组中,未检测到肿瘤中抗体摄取百分比与肿瘤消退之间的相关性。
这些实验结果表明,热疗提高了碘-131标记的抗CEA单克隆抗体对裸鼠人结肠腺癌异种移植瘤的有效性。本研究为临床实践中热疗与RIT产生的低剂量放疗联合应用提供了理论依据。